Literature DB >> 30262888

Reforming China's drug regulatory system.

Lili Xu1, Huijun Gao2, Kenneth I Kaitin3, Liming Shao1.   

Abstract

Mesh：

Year:  2018        PMID： 30262888     DOI： 10.1038/nrd.2018.150

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

1.  Where Can Patients Obtain Information on the Preapproval Access Pathway to Investigational Treatment in Japan? A Survey of Patient Advocacy Organizations' Websites.

Authors:  Haruka Nakada; Kyoko Takashima
Journal:  Clin Pharmacol Drug Dev       Date:  2019-10-08

Review 2.  Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective.

Authors:  Yifan Diao; Mingshuang Li; Zhiran Huang; Jing Sun; Yoke Ling Chee; Yunali Liu
Journal:  Risk Manag Healthc Policy       Date:  2019-12-18

3.  Drivers of Start-Up Delays in Global Randomized Clinical Trials.

Authors:  Jennifer Lai; Leila Forney; Daniel L Brinton; Kit N Simpson
Journal:  Ther Innov Regul Sci       Date:  2020-09-21       Impact factor: 1.778
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.